Dr. Stephen (Steven) Klein

speaker

467 appearances 1 recordings 1 series first heard Jul 2026 last heard 2 Jul

Dr. Stephen (Steven) Klein’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

Appearances

newest first · ▶ plays the moment

RECOVERable: Mental Health and Addiction Experts Answer Your Questions · Ozempic and Cravings: How GLP-1 Drugs Work for Addiction · 2 Jul 2026 podcast

What's interesting also, though, is that for me doesn't mean we don't use them.

For example, the medications that we discussed last episode, buprenorphine, methadone, and naltrexone, I know what happens when a patient comes off buprenorphine.

Their cravings do return.

They do have withdrawal symptoms.

So I don't think that disqualifies these medications from being used.

We have a little bit of hesitancy, I think, as a society to think about a medication that's being used for our lifetimes, but we also seem to be pretty selective.

Most statins are prescribed for a lifetime.

Most SSRIs are considered long-term medications.

So I think, for me, again, it comes down to the risk-benefit analysis of these medications.

For right now, I think that they're really helping the patients that they're being prescribed to.

I think going back to something we discussed last episode, number needed to treat, the lower the number needed to treat, the more efficacious a medication is.

The number needed to treat for Ozempic, Wegovy, Zetbound, and Monjorno are also in the two to three range.

So when you start combining these things like buprenorphine plus semaglutide, naltrexone plus semaglutide, I think these things will be additive and they'll give patients the best shot, the best chance at recovery, the best chance at abstinence, and then getting to the deeper questions and being able to do some of the deeper work.

Yeah, I think they'll definitely be additive.

Also, kind of building from our last conversation, one of the major barriers we have in addiction medicine is just accessibility to these medications.

So I certainly...

am encouraged by the new wave of addiction medicine treatments.

I also think we need to kind of keep our focus broad and that we should be increasing accessibility, not only to GLP-1s, but also buprenorphine and naltrexone and methadone.

I think the more treatment options that are available, the better.

And I think the more that we can curtail our treatment planning to individual patients, their experience, their individual stigmas and societal stigmas, the better outcomes we'll have as a society.

Showing 341–360 of 467 · page 18 of 24